

Date of preparation: 2022-10-18

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Credit Committee of the European Bank for Reconstruction and Development approves financing for the Company

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

The Management Board of Mabion S.A. (“Company”, “Issuer”) hereby informs that on 18 October 2022, it received information that the Credit Committee of the European Bank for Reconstruction and Development (“EBRD”) has given its approval for the provision of financing to the Company in the form of a secured long-term loan amounting to USD 15 million (“Loan”).

The Loan is intended in particular to finance the expansion and modernisation of the Issuer’s current facility located in Konstantynów Łódzki. The investment is related to the commercial contract manufacturing carried out under an agreement with Novavax, Inc. of which the Company informed, *inter alia*, in Current Reports no. 52/2021 of 8 October 2021 and no. 31/2022 of 22 September 2022, as well as other potential CDMO (Contract Development and Manufacturing Organization) projects.

As agreed with the EBRD, the funding will also be partly used to refinance Company’s existing debt.

The Loan is to be granted by the EBRD for a period of 2 years as of signing the agreement, with early repayment possible. It will bear interest at a variable rate based on the SOFR, plus EBRD’s margin.

The EBRD Credit Committee’s approval represents an interim step in the process of obtaining the funds and is not tantamount to the completion of this process and the EBRD’s commitment to disburse the resources. The availability of the latter will depend, among other things, on entering into a credit agreement with the EBRD, of which the Issuer will inform in a separate report, and on the fulfilment of the conditions precedent, including the establishment of appropriate collateralisation.